The neuropeptide Y system is linked to a more severe form of alcohol dependence
September 23, 2008Previous animal research showed an association between the neuropeptide Y (NPY) pathway and its three receptor genes and response to alcohol and cocaine. A new study has examined the relationship of the human NPY system with alcohol dependence (AD), with and without withdrawal symptoms, and cocaine dependence. Two receptor genes in particular, NPY2R and NPY5R, were found to be associated with a more severe subtype of AD – characterized by withdrawal symptoms or coexisting alcohol and cocaine dependence – and cocaine dependence.
Results will be published in the December issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.
"Very little is known about the association of the NPY system and alcohol dependence and withdrawal in humans," said Tatiana M. Foroud, director of the division of hereditary genomics at the Indiana University School of Medicine and senior author of the study. "The majority of information comes from studies done on rats and mice, research which suggests that animals that prefer alcohol are genetically different in their expression of NPY in the brain."
These animals, she added, are selectively bred to prefer drinking alcohol and are meant to mimic AD in humans. "Rats that prefer alcohol have lower levels of NPY, which makes them more excitable and thus more likely to experience seizures when they are not allowed to drink alcohol," said Foroud. "When doses of NPY are administered to alcohol-drinking rats that are experiencing withdrawal, the withdrawal seizures are reduced. Since rats are genetically very similar to humans, these results could implicate that variants of the NPY gene or the receptor genes may be associated with alcohol dependence and seizures in humans."
"Recent human genetic linkage studies have suggested that polymorphisms of the NPY gene may contribute to risk of increased alcohol use, but these results have been inconsistent," added Todd E. Thiele, professor and director of research services in the department of psychology at the University of North Carolina at Chapel Hill. "What is novel about the present paper is that the authors have taken the human genetic linkage studies a step further by examining polymorphisms of NPY receptor genes."
Researchers genotyped 39 single nucleotide polymorphisms (SNPs) across NPY and its three receptor genes (NPY1R, NPY2R and NPY5R) in a sample of 1,923 subjects from 219 multiplex alcoholic families of European-American descent participating in the Collaborative Studies on the Genetics of Alcoholism (COGA) study. Variation in these genes was first analyzed for any association with AD, and second, analyzed for associations with symptoms of alcohol withdrawal, cocaine dependence, and coexisting alcohol and cocaine dependence.
"We found an association with the NPY2R and NPY5R receptor genes and alcohol withdrawal," said Foroud. "In other words, certain alleles are genetically transmitted more often to, and are more common in, AD people who experienced alcohol-withdrawal symptoms compared to AD people who did not experience any symptoms. That means that alcoholics who suffer withdrawal symptoms when they try to stop drinking may be genetically different than alcoholics who do not suffer these symptoms when they cut down or stop drinking."
"While these receptors have been implicated in animal work," noted Thiele, "this is the first observation with human genetic data. While results from this study do not provide a cure for alcoholism, they do show us a potential avenue for future clinical work. In other words, while much work is yet needed, the present study suggests that pursuing the Y2 receptor may be fruitful."
Foroud wholeheartedly concurs. "First, we know from the animal research how alcohol and NPY interact. Second, we know from our research that NPY1R and NPY2R are associated with withdrawal symptoms and seizures in humans. Knowing both pieces of information supports what researchers in the animal literature have been saying in their articles for several years, namely, that treatments for AD should target antagonists in the NPY2R gene and agonists in the NPY1R gene. This pharmacological treatment would not eradicate AD or cure it, in fact it might only help those people who consume more alcohol and/or experience seizures or other withdrawal symptoms. But it's a start."
Foroud and her colleagues have begun to further examine NPY, NPY receptor genes, anxiety and drinking. "This also derives from the animal literature," she said. "Rats that prefer drinking alcohol have lower levels of NPY in their brain, and express higher levels of stress in tests compared to rats that do not like to drink alcohol. If you translate this finding to humans, the NPY gene could be associated in human beings who perhaps slipped into AD because they could not adapt to stressful situations. They gradually increased their alcohol consumption to deal with increasing stress."
Source: Alcoholism: Clinical & Experimental Research
-
Brain DNA 'remodeled' in alcoholism
Apr 02, 2008 |
4.8 / 5 (16) |
1
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (30) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (3) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (1) |
0
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Team isolates nerve cells involved in storing long term memory and gene proteins associated with them
(Medical Xpress) -- A research team in Taiwan has succeeded in isolating two nerve cells in fruit fly brains that are believed to be the major players in allowing for the formation of long term memories. Furthermore, ...
News of plaque-clearing drug tops week of major advances against Alzheimer's disease
In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease. At the same time, the White House and members of Congress are proposing increases in Alzheimer's research ...
51 minutes ago |
not rated yet |
1
To avoid early labor and delivery, weight and diet changes not the answer
One of the strongest known risk factors for spontaneous or unexpected preterm birth any birth that occurs before the 37th week of pregnancy, most often without a known cause is already having had one. For women ...
4 minutes ago |
not rated yet |
0
|
Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease
St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.
20 minutes ago |
not rated yet |
0
S.Africa in $208 mln AIDS drug venture with Swiss Lonza
South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.
Medicine & Health / HIV & AIDS
1 hour ago |
not rated yet |
0
The power of estrogen -- male snakes attract other males
A new study has shown that boosting the estrogen levels of male garter snakes causes them to secrete the same pheromones that females use to attract suitors, and turned the males into just about the sexiest ...
Could Venus be shifting gear?
(PhysOrg.com) -- ESAs Venus Express spacecraft has discovered that our cloud-covered neighbour spins a little slower than previously measured. Peering through the dense atmosphere in the infrared, the ...
Experts reveal how plants don't get sunburn
(PhysOrg.com) -- Experts at the University of Glasgow have discovered how plants survive the harmful rays of the sun.
Fool's gold may prove an unlikely alternative to overexploited catalytic materials
Catalytic materials, which lower the energy barriers for chemical reactions, are used in everything from the commercial production of chemicals to catalytic converters in car engines. However, with current catalytic materials ...
SLAC, Stanford team focuses on high-energy electrons to treat cancer
Accelerator physicists at SLAC and cancer specialists from Stanford are working on a new technology that could dramatically reduce the time needed for cancer radiation treatments. The team ran an initial experiment ...
Unpicking HIV’s invisibility cloak
Drug researchers hunting for alternative ways to treat human immunodeficiency virus (HIV) infections may soon have a novel targetits camouflage coat. HIV hides inside a cloak unusually rich in a sugar ...